Clinical Effects of Two Oral Bioactive Collagen Peptides On Skin Properties and Aging Hallmarks

Summary

This randomized, controlled clinical trial evaluated whether daily oral intake of a collagen peptides supplement improved age-associated skin beauty parameters in healthy women with visible facial wrinkles. A total of 68 healthy female volunteers between 35 and 65 years of age (both inclusive) with noticeable facial wrinkles were initially enrolled in this randomized, double-blind, parallel-group clinical study. Participants were allocated in a 1:1 ratio to receive either the active control (n = 34) or avvera™ (n = 34). One participant in the active control group withdrew from the study due to personal reasons and was excluded from the final analysis. Consequently, 67 participants completed the study and were included in the efficacy analyses (active control: n = 33; avvera™: n = 34). Participants consumed one 2,500 mg sachet per day, diluted in water or another beverage, while maintaining their usual diet and skincare routines and avoiding other oral supplements or intensive cosmetic procedures for 8 weeks.

The main objectives were to determine whether each collagen supplement, considered independently, (1) improved facial skin elasticity, firmness, and fatigue; (2) reduced wrinkle area, depth, and volume in the crow's-feet region; and (3) enhanced skin hydration and barrier function. At baseline (Day 0) and at weeks 4 and 8, participants attended clinic visits where skin elasticity, firmness, and fatigue were measured with a Cutometer; wrinkles were assessed by VISIA-CR/PRIMOS imaging; skin hydration was measured with a Corneometer; and transepidermal water loss on the cheek was quantified with a Tewameter. The study was designed to assess the efficacy of each product separately, without formal head-to-head comparison between them.

Conditions

• Skin Ageing
• Facial Wrinkles - Rough Texture - Hyperpigmentation
• Skin Hydration in Healthy Volunteers

Interventions

OTHER

Dietary Supplement: Collagen Peptides Supplement

Participants will be provided with the Collagen peptides supplement and instructed to take one sachet orally once daily for 8 weeks (one 2,500 mg sachet diluted in water or another beverage, preferably in the morning at approximately the same time each day). Efficacy will be evaluated at baseline and at approximately 4 and 8 weeks after the first intake by measuring facial skin elasticity, firmness, and fatigue with a Cutometer®, wrinkle area/depth/volume in the crow's-feet region with VISIA-CR®/PRIMOS® 3D imaging, skin hydration with a Corneometer®, and skin barrier function (transepidermal water loss) on the cheek with a Tewameter®. The product is a pure hydrolyzed bovine collagen peptides powder (2,500 mg per sachet), free of artificial additives/E-numbers and compliant with EU food regulations. All procedures and instrumental measurements take place at Bionos Biotech S.L. facilities.

OTHER

Dietary Supplement: Competitor's Collagen Supplement

Participants will be provided with the Competitor's collagen supplement and instructed to take one sachet orally once daily for 8 weeks (one 2,500 mg sachet diluted in water or another beverage, preferably in the morning at approximately the same time each day). Efficacy will be evaluated at baseline and at approximately 4 and 8 weeks after the first intake using the same non-invasive methods: Cutometer® (elasticity, firmness, fatigue), VISIA-CR®/PRIMOS® 3D imaging (crow's-feet wrinkle area, depth, and volume), Corneometer® (facial skin hydration), and Tewameter® (transepidermal water loss on the cheek). The product is a pure hydrolyzed bovine collagen peptides powder (2,500 mg per sachet), currently marketed as a collagen supplement and compliant with international food-safety regulations. All procedures and instrumental measurements take place at Bionos Biotech S.L. facilities.

Sponsors & Collaborators

• Bionos Biotech S.L.

  lead INDUSTRY

Principal Investigators

• Adela Serrano Gimeno, PhD · Bionos Biotech S.L. , LabAnalysis Life Science

Study Design

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

35 Years

Max Age

65 Years

Sex

FEMALE

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2025-02-26

Primary Completion

2025-04-23

Completion

2025-04-23

Countries

• Spain

Study Locations